Portfolio company Rome Therapeutics wound down and was acquired by Pretzel Therapeutics for undisclosed terms.
Rome Therapeutics is a biotechnology company focused on developing therapies that target the 'dark genome' and LINE-1 RT inhibitors for cancer, autoimmune, and neurodegenerative diseases
Rome Therapeutics is a biotechnology company focused on developing therapies that target the 'dark genome' and LINE-1 RT inhibitors for cancer, autoimmune, and neurodegenerative diseases. The company employs machine learning and has a proprietary database for drug discovery.